Skip to content

How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study)

How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study)

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04080388
Acronym
HOPE-HF
Enrollment
200
Registered
2019-09-06
Start date
2019-09-30
Completion date
2021-09-30
Last updated
2019-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure Acute

Brief summary

The readmission of Heart Failure (HF) patients for exacerbation HF within 30-day is unmet goal. The mail reason for readmission is excessive accumulation of fluid in patient's lung. According our data (1,2) around 40% of HF patient have excessive lung fluid at discharge from HF hospitalization (unacceptable residual congestion on discharge). In other words, around 40% patients are discharged from HF hospitalization prematurely when they are not ready to be discharged. Only 60% of HF patients are discharged from HF admission with acceptable level of residual pulmonary congestion (2). There are some techniques to assess readiness of HF patients for discharge. Pulmonary congestion (lung fluid accumulation) may be assessed non-invasively by measurement Brain Natriuretic Peptide (BNP), (3,4), by lung ultrasound (LUS), (5-7) and by Lung Impedance (LI) method (1,2). LUS is operator depended technique. LI and BNP techniques are most reliable methods (2) and easy to use.

Interventions

DIAGNOSTIC_TESTLung Impedance Device

The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.

DRUGAnti-congestive treatment

Continuation of in-hospital anti-congestive treatment

Sponsors

Hillel Yaffe Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acute Heart Failure Patients Prior to Hospital Discharge

Exclusion criteria

* No Cardiac Resynchronization Device Implanted During Current Hospitalization * Estimated glomerular filtrating rate (GFR) less than 30 ml/min

Design outcomes

Primary

MeasureTime frameDescription
Prevention of heart failure re-admission30 days30-day re-admission rates will be compared between the two groups

Countries

Israel

Contacts

Primary ContactMichael Kleiner Shochat, MD, PhD
shochat1@gmail.com972-50-6246926

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026